Research Overview of Fluconazole Formulations
Forcan 50 mg is a fluconazole-based pharmaceutical formulation manufactured by Cipla for laboratory research applications. Fluconazole represents a triazole antifungal compound extensively studied in mycological research and fungal cell biology investigations. Researchers examining antifungal mechanisms and fungal resistance patterns frequently evaluate fluconazole formulations in controlled laboratory environments. This particular formulation provides researchers with standardised dosing units for consistent experimental protocols across multiple study designs.
Laboratory investigations utilising fluconazole compounds contribute to our understanding of fungal pathogenesis, drug resistance mechanisms, and antifungal efficacy testing. The compound’s well-characterised pharmacological profile makes it a valuable reference standard in comparative antifungal studies. Research teams at Stroid UK Shop regularly incorporate fluconazole formulations into their experimental frameworks when studying candida species, cryptococcal organisms, and other clinically relevant fungi.
Laboratory Applications and Research Scope
Fluconazole formulations like Forcan serve multiple research purposes in academic and pharmaceutical laboratory settings. Mycology researchers examine this compound’s interaction with fungal cytochrome P450 enzymes, specifically investigating its effects on ergosterol biosynthesis pathways. These studies contribute valuable data to antifungal drug development programmes and resistance mechanism research initiatives.
Pharmaceutical researchers studying antifungal compounds often compare fluconazole’s activity profile against newer triazole derivatives and alternative antifungal classes. Such comparative studies help identify optimal therapeutic strategies and inform future drug development directions. Additionally, researchers investigating fungal biofilm formation frequently evaluate fluconazole’s effects on biofilm development and maintenance in various fungal species.
Academic institutions conducting antimicrobial surveillance programmes utilise fluconazole formulations to establish baseline susceptibility profiles for clinical fungal isolates. These surveillance studies provide critical epidemiological data regarding antifungal resistance trends and inform clinical practice guidelines. The standardised nature of pharmaceutical-grade formulations like Forcan ensures reproducible results across different research laboratories.
Product Specifications
| Parameter | Specification |
|---|---|
| Active Compound | Fluconazole |
| Strength | 50 mg |
| Manufacturer | Cipla |
| Form | Tablet formulation |
| Storage | Room temperature, dry conditions |
| Molecular Formula | C₁₃H₁₂F₂N₆O |
| CAS Registry | 86386-73-4 |
Research institutions requiring additional compounds for comprehensive studies can explore related categories including selective androgen receptor modulators and research peptides for diverse experimental applications.
Research Compliance and Laboratory Use
Forcan 50 mg is supplied exclusively for in-vitro laboratory research purposes and must not be used for human consumption or therapeutic applications. Research institutions must ensure appropriate handling protocols and storage conditions are maintained throughout the investigation period. All experimental work should be conducted by qualified researchers within approved laboratory facilities equipped with appropriate safety measures and waste disposal systems.
